Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi

Chikowe, Ibrahim; Domingo, McDonald; Mwakaswaya, Vasco; Parveen, Shagufta; Mafuta, Chitsanzo; Kampira, Elizabeth

doi:10.1186/s13104-019-4398-6

Cited by 8 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the prevailing perspective suggests that TAPs are less likely to induce metabolic abnormalities compared to AAPs, our research, along with findings from other research groups [ 33 , 34 ], have demonstrated metabolic dysfunction induced by TAPs. In a cohort of SZ patients receiving CPZ monotherapy for over a decade, the prevalence of metabolic syndromes was found to be 31% [ 35 ].…”

Section: Discussioncontrasting

confidence: 39%

High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects

Chen,

Gao,

et al. 2024

Transl Psychiatry

View full text Add to dashboard Cite

Atypical antipsychotics (AAPs) are primary medications for schizophrenia (SZ). However, their use is frequently associated with the development of adverse metabolic effects, and the mechanisms behind these negative effects remain inadequately elucidated. To investigate the role of macrophage migration inhibitory factor (MIF) in regulating antipsychotic-induced metabolic abnormalities, between 2017 and 2020, a cross-sectional study was conducted, involving 142 healthy individuals and 388 SZ patients undergoing treatment with either typical antipsychotic (TAP) or AAP medications. Symptoms of SZ patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), and measurements of metabolic indices and plasma MIF levels were performed on all individuals. A significant increase in plasma MIF levels was observed in groups receiving five major AAP monotherapies in comparison to healthy controls (all p < 0.0001). There was no such increase shown in the group receiving TAP treatment (p > 0.05). Elevated plasma MIF levels displayed a notable correlation with insulin resistance (β = 0.024, p = 0.020), as well as with the levels of triglycerides (β = 0.019, p = 0.001) and total cholesterol (β = 0.012, p = 0.038) in the groups receiving AAPs. However, while the TAP group also displayed certain metabolic dysfunction compared to healthy controls, no significant association was evident with plasma MIF levels (all p > 0.05). In conclusion, plasma MIF levels exhibit a distinctive correlation with metabolic abnormalities triggered by AAPs. Hence, there is potential for further development of MIF as a distinctive marker for monitoring adverse metabolic effects induced by AAPs in clinical settings.

show abstract

Section: Discussioncontrasting

confidence: 39%

High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects

Chen,

Gao,

et al. 2024

Transl Psychiatry

View full text Add to dashboard Cite

show abstract

“…Drugs used to treat neoplasms generally have a high prevalence of ADRs. The prevalence of ADRs is also known to be highly associated with medications for mental and behavioral disorders; at least one adverse drug event has been reported in all patients treated with haloperidol and chlorpromazine 29 . For patients with neoplasms or mental and behavioral disorders, careful attention to the signs of ADRs may prevent their development.…”

Section: Discussionmentioning

confidence: 99%

Effects of the number of drugs used on the prevalence of adverse drug reactions in children

Sugioka

Tachi

Mizui

et al. 2020

Sci Rep

View full text Add to dashboard Cite

In pediatric individuals, polypharmacy would increase the prevalence of adverse drug reactions (ADRs). However, there is no report on the ADR increase adjusted for the influence of concomitant disease types. We conducted a retrospective study in pediatric patients to determine whether polypharmacy is a risk factor for ADR development, after the adjustment. Patients aged 1–14 years on medication who visited Gifu Municipal Hospital (Gifu, Japan) were included. We evaluated patient characteristics, ADR causality, ADR classification and severity, and ADR-causing drugs. We examined the association between ADR prevalence and number of drugs used. We performed multiple logistic regression analyses to investigate risk factors for ADR development. Of 1330 patients, 3.5% sought medical attention for ADRs. ADR causality was most often assessed as “possible,” with gastrointestinal ADRs being the most common. Grade 1 ADRs were the most and antibiotics were the most common suspected ADR-inducing drug. The multiple logistic regression analysis showed that ≥ 2 or ≥ 4 drug use, neoplasms, mental and behavioral disorders, and circulatory system diseases significantly increased ADR prevalence. Polypharmacy increased the prevalence of ADR resulting in hospital visits in children, after adjusting for the influence of disease types. Therefore, proactive polypharmacy control measures are necessary for children.

show abstract

“…While the prevailing perspective suggests that TAPs are less likely to induce metabolic abnormalities compared to AAPs, our research, along with findings from other groups [33,34],…”

Section: Discussionmentioning

confidence: 45%

High circulating MIF levels indicate the association with atypical antipsychotic-induced metabolic adverse effects

Qi,

Chen,

Gao

et al. 2023

Preprint

View full text Add to dashboard Cite

Atypical antipsychotics (AAPs) are first-line medications for schizophrenia (SZ). However, their use is frequently associated with the development of metabolic adverse effects, and the mechanisms behind these negative effects remain inadequately elucidated. To investigate the role of macrophage migration inhibitory factor (MIF) in regulating antipsychotic-induced metabolic abnormalities, we recruited 142 healthy individuals and 388 SZ patients who had been receiving either typical antipsychotic (TAP) or AAP treatments. Subsequently, we conducted assessments of metabolic indices and measured plasma MIF levels, followed by a comprehensive statistical analysis to investigate the connection between MIF levels and metabolic dysfunction. A significant increase in plasma MIF levels was observed in groups receiving monotherapies with five major AAPs in comparison to healthy controls (all p < 0.0001). There was no such increase shown in the group receiving TAP treatment (p > 0.05). Elevated plasma MIF levels displayed a notable correlation with insulin resistance (β = 0.024, p = 0.020), as well as with the levels of triglycerides (β = 0.019, p = 0.001) and total cholesterol (β = 0.012, p = 0.038) in the groups receiving AAPs. However, while the TAP group also displayed some degree of metabolic dysfunction compared to healthy controls, no significant association was evident with plasma MIF levels (all p > 0.05). In conclusion, Plasma MIF levels exhibit a distinctive correlation with metabolic abnormalities triggered by AAPs. Thus, MIF could be further developed as a unique marker to monitor AAP-induced metabolic adverse effects in clinical settings.

show abstract

Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi

Cited by 8 publications

References 30 publications

High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects

High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects

Effects of the number of drugs used on the prevalence of adverse drug reactions in children

High circulating MIF levels indicate the association with atypical antipsychotic-induced metabolic adverse effects

Contact Info

Product

Resources

About